コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 notype and freedom from first grade > or =3A rejection episode.
2 t accepted the allograft permanently after a rejection episode.
3 redict functional outcome following an acute rejection episode.
4 months, four patients have not experienced a rejection episode.
5 ment with pulse steroid therapy to treat the rejection episode.
6 418 serum samples, including 35 paired to a rejection episode.
7 Among 98 subjects, 37% had >/=1 rejection episode.
8 and grafts after successful treatment of the rejection episode.
9 ents were symptomatic and 7 did not note the rejection episode.
10 c tacrolimus concentrations may induce acute rejection episodes.
11 nd in the early post-ITx period during first rejection episodes.
12 mild (n=4), moderate (n=2), and severe (n=1) rejection episodes.
13 d continuous vigilance is required to detect rejection episodes.
14 of bowel on initial endoscopy, and number of rejection episodes.
15 ay in fact be missed concordant kidney acute rejection episodes.
16 ab and three Thymoglobulin patients suffered rejection episodes.
17 al function was attained in patients without rejection episodes.
18 There were no acute rejection episodes.
19 y initial immunosuppression to prevent early rejection episodes.
20 jection and would resolve after treatment of rejection episodes.
21 recipients at increased risk for early acute rejection episodes.
22 y of renal function with a low risk of acute rejection episodes.
23 ) survival, complications, and biopsy-proven rejection episodes.
24 ymocyte Globulin) was used to treat putative rejection episodes.
25 n episodes, and seven experienced mild acute rejection episodes.
26 and were evaluated retrospectively regarding rejection episodes.
27 s or the incidence of biopsy-confirmed acute-rejection episodes.
28 d after immunosuppressive therapy in 9 of 11 rejection episodes.
29 .2%) patients developed a total of six acute rejection episodes.
30 he absence of rejection would predict future rejection episodes.
31 gnificant increase in the incidence of acute rejection episodes.
32 ts on subsequent graft survival or number of rejection episodes.
33 oup of children with no early clinical acute rejection episodes.
34 ifically home to the graft epithelium during rejection episodes.
35 y predict the subsequent occurrence of acute rejection episodes.
36 p, current pharmacological regimen, and late rejection episodes.
37 erved between patients with or without early rejection episodes.
38 correlated positively with mild and moderate rejection episodes.
39 E patients who experienced greater than four rejection episodes.
40 grafts, but not in recipients with multiple rejection episodes.
41 equent (P=0.034) and earlier (P=0.065) acute rejection episodes.
42 resulted in a significant reduction in acute rejection episodes.
43 time points compared with eyes without graft rejection episodes.
44 biopsy, caused by hepatitis C recurrence or rejection episodes.
45 -DSA showed the highest likelihood to suffer rejection episodes.
46 3 years (mean, 28 months) without subsequent rejection episodes.
47 o differences in incidences of biopsy-proven rejection episodes.
48 drawn due to return of underlying disease or rejection episodes.
49 or glaucoma surgery (P < 0.0001) and a prior rejection episode (0.0023) were the significant risk fac
50 ed viruria was associated with more putative rejection episodes (0.62 vs. 0.33 per patient, P=0.006)
53 on, p < 0.05) and hemodynamically comprising rejection episodes (1.3 +/- 1.9 vs. 0.7 +/- 1.3, overall
54 /- 7%), despite an increased number of early rejection episodes (1.7 +/- 1.6 vs. 0.7 +/- 1.3, overall
55 . 25%, P=0.04), more likely to have a second rejection episode (13% vs. 4%; P=0.03), or to have recei
58 onders exhibited a higher incidence of acute rejection episodes (26%) than either basiliximab-treated
59 2 months, respectively (P<0.001); more acute rejection episodes 28.2% vs. 13.5% (P=0.012); and increa
60 total of 13 (31%) of 42 recipients developed rejection episodes 3 to 49 days after transplantation.
61 uency in the group of patients with multiple rejection episodes (35.1% and 18.4%) compared to rejecti
62 e significantly more likely to have an acute rejection episode (39% vs. 25%, P=0.04), more likely to
63 te), and all predisposed to subsequent acute rejection episodes (4/4), whereas there were no rejectio
65 that S patients had fewer post-30 day first rejection episodes (5.4%) when compared with the C group
70 e the incidence and clinical course of graft rejection episodes after Descemet membrane endothelial k
72 survival and reduced the incidence of acute rejection episodes after renal transplantation compared
77 duction of the incidence and the severity of rejection episodes, although we need to follow-up larger
78 id-resistant or Banff grades II or III acute rejection episodes among 14%, 55% (P=0.08), and 71% (P=0
79 ction in the incidence and severity of acute rejection episodes among patients maintained on tacrolim
82 pretransplant regulation, seven had an acute rejection episode and four of these experienced graft lo
84 of keratoplasty may be used to anticipate a rejection episode and/or to prevent an allograft rejecti
85 nd 4 mg/day resulted in lower rates of acute rejection episodes and efficacy failure than the 1 mg/da
91 or third-party MSCs resulted in reversal of rejection episodes and prolongation of islet function in
92 variations in susceptibility to early graft rejection episodes and recurrence of hepatitis C infecti
94 in outcome measures: Cumulative incidence of rejection episodes and rejection irreversibility rate.
95 ents had a greater frequency and severity of rejection episodes and required more immunosuppression.
96 us therapy benefited the resolution of acute rejection episodes and significantly reduced the risk of
97 cipients, i.e., patients with no prior acute rejection episodes and stable renal function ("stable" p
98 and the incidence and severity of the acute rejection episodes and to determine the safety and toler
99 id not develop rejection, 123 who showed one rejection episode, and 57 patients who suffered from mul
100 einuria, the occurrence of a post-PAK kidney rejection episode, and interval between kidney and pancr
102 dence of acute tubular necrosis (ATN), acute rejection episodes, and causes of graft failure in perit
104 recipients is a major risk factor for graft rejection episodes, and it has significant financial imp
105 rophylactic drug, organ type, recipient age, rejection episodes, and maintenance immunosuppression re
106 rum creatinine level, number and severity of rejection episodes, and patient and graft survival rates
107 neal vascularization, surgical complication, rejection episodes, and postoperative medication were co
108 cluding donor and recipient characteristics, rejection episodes, and serology were prospectively reco
109 severe rejection, three experienced moderate rejection episodes, and seven experienced mild acute rej
110 CV recurrence, the number and grade of acute rejection episodes, and the histological course of HCV r
111 that occurrence, timing, and number of acute rejection episodes are associated with increased risk of
114 n the MMF withdrawal group suffered an acute rejection episode as opposed to 1 of 45 in the control g
115 ties, on the incidence and severity of acute rejection episodes as well as its tolerability were eval
117 = 4), post keratoplasty patients with active rejection episodes associated with vessels; and group 4
118 The Kaplan-Meier cumulative probability of a rejection episode at 1 and 2 years was 1% and 1%, respec
119 Kaplan-Meier cumulative probability of a rejection episode at 3, 6, 12, and 24 months was 0%, 0.4
120 tion in the incidence of biopsy-proven acute rejection episodes at 12 months posttransplant (43% vs.
121 therapy and who had not experienced an acute rejection episode before month 6, serum creatinine level
122 surgery (HR, 5.23 [95% CI, 1.47-7.33]), and rejection episodes before PK failure (HR, 3.28 [95% CI,
125 with less early CNI nephrotoxicity and fewer rejection episodes, but comparable chronic arteriolar to
126 sive drug that has reduced the rate of acute rejection episodes by more than 40% in phase III trials
127 yzed for time to first repeat and late acute rejection episodes by race, age at transplantation, and
129 the rejector group, 19 patients presented 26 rejection episodes: clinically suspected (n=19) and biop
130 , fewer endocrine disorders, and fewer acute rejection episodes comparing adjunctive MMF and Tacro vs
131 d the asymptomatic nature of most histologic rejection episodes, controversy exists regarding the nee
133 vs. cadaveric), native liver disease, acute rejection episodes, cytomegalovirus (CMV) infection, and
135 biopsy-proven (Banff 1993 criteria) ongoing rejection episodes despite prior treatment with pulse an
137 ipient gender distribution, HLA studies, and rejection episodes did not correlate with AIH recurrence
138 It was interesting that there were seven rejection episodes documented by biopsy at the approxima
140 oid, even a weak one, was protective against rejection episodes during the second year after DMEK, wh
142 lem, eight terminated because of one or more rejection episodes, four terminated because of adverse e
143 fter transplantation and monitored for acute rejection episodes, graft function, and graft survival.
144 ailure, occurrence of biopsy-confirmed acute rejection episodes, graft loss, or death, and various se
145 ncidence and severity of biopsy-proven acute rejection episodes, graft survival, patient survival, in
147 h recipients with a history of > or =1 acute rejection episode had a higher serum creatinine level vs
149 ial fraction (30%) of biopsy-confirmed acute rejection episodes have a component of AHR as judged by
153 adjusting for DSA_MFI_max, C4d, or previous rejection episodes, however lost their independent relat
154 were found to be at increased risk for acute rejection episodes if the allograft was mismatched for t
156 d the onset of the first biopsy-proven acute rejection episode in patients with DGF from 29+/-43 days
159 between a transplant in the second eye and a rejection episode in the first eye (KC P = .19, FED P =
161 overall relative risk of having at least one rejection episode in those who received fish oil was 0.9
164 ection episodes (4/4), whereas there were no rejection episodes in ASK transplants without ATN (0/32;
165 phase II assessment of prophylaxis of acute rejection episodes in deceased donor renal allografts.
168 roids has proven to be effective in reducing rejection episodes in high-risk organ and islet cell tra
169 TN) on graft survival and incidence of acute rejection episodes in infant and small child recipients
170 and long-term rates of repeat and late acute rejection episodes in pediatric heart transplant (PHTx)
173 o significantly decrease the number of acute rejection episodes in renal transplant recipients during
174 eported and presumed isolated pancreas acute rejection episodes in simultaneous pancreas kidney patie
177 eatinine less than 300 mumol/L with no acute rejection episodes in the preceding 6 months were enroll
182 e analysis demonstrated more moderate-severe rejection episodes (ISHLT > or = IIIA) at 2 months (0.83
183 intestinal allograft, delay in treatment of rejection episodes may result in rejection of the intest
184 fter randomization 23 patients experienced a rejection episode: MMF/pred (27.0%), MMF/CsA (6.8%) and
186 d IL-10 genes were not associated with acute rejection episodes, nor was the IL-4 receptor alpha-chai
188 nsplant recipients and, in many cases, acute rejection episodes occur because of escape of donor-reac
192 ; Tac/MMF, 2.2%; triple therapy, 2.2%); Most rejection episodes occurred during the first 6 months of
198 eterioration of graft function resulted from rejection episodes occurring more than 2 years after tra
200 ents with a positive virtual XMs showed more rejection episodes of any types when comparing with pati
201 ollow-up of 8 months, number and severity of rejection episodes of protocol patients did not differ f
203 cal course was complicated by an early acute rejection episode on posttransplant day (PTD) 6, that wa
205 the incidence of acute rejection, number of rejection episodes or 1-year allograft survival among Bw
206 to the regimen when patients developed acute rejection episodes or adverse effects to steroids or MMF
207 it did not further reduce the rate of acute rejection episodes or increase graft survival compared t
210 etween particular cytokine profile and early rejection episodes, our data strongly suggest an associa
212 er incidence of subsequent antibody-mediated rejection episodes (P < 0.001), but reduced death-censor
216 er rate and higher histologic grade of acute rejection episodes, particularly proximate to the onset
217 onrandomized cohorts were compared for acute rejection episodes, patient and graft survival rates, re
221 the graft tubular epithelium during clinical rejection episodes, predicting a causal role for CD103+C
223 comitant with the bout of HUS, namely, acute rejection episodes prior to (n=2) or during (n=3), and 2
225 th the age or sex of the donor or recipient, rejection episodes, renal biopsy, or drug-induced nephro
226 emergency hospitalizations, renal biopsies, rejection episodes, renal function, and blood concentrat
229 four histologically diagnosed, severe acute rejection episodes resulted in graft failure before reso
230 tion, survival of patients and grafts, acute rejection episodes, serum creatinine values, adverse eve
232 from six patients (FCL: 217) coincided with rejection episodes, six samples from three patients (FCL
233 had a 15 times lesser risk of experiencing a rejection episode than DSEK eyes (95% confidence limit [
234 nce of late (>6 months posttransplant) acute rejection episodes than did the LURD recipients (8.6% vs
236 unction displayed a lower incidence of acute rejection episodes than those with later recovery of fun
237 The sixth allograft had an early, severe rejection episode that limited renal growth and attainme
238 lotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by i
239 lotransplants, CTA recipients can experience rejection episodes that are presumed to be mediated by i
244 ere collected on patient and graft survival, rejection episodes, urinary tract infection (UTI) requir
245 re higher in patients who subsequently had a rejection episode versus those who had no rejection (22.
249 However, the incidence of a first reversible rejection episode was significantly higher for simultane
252 , the incidence of moderate and severe acute rejection episodes was found to be significantly lower a
254 ariate analysis, the cumulative incidence of rejection episodes was influenced by recipient age (P =
260 roscopy images before, during, and after the rejection episode were analyzed and compared with a case
263 ients (1995-2005), 108 patients with a first rejection episode were selected for study using strict i
264 rior glaucoma surgeries, and occurrence of a rejection episode were the significant risk factors for
267 led that grades indicating more severe acute rejection episodes were associated with a greater probab
272 ring the first posttransplant year the acute rejection episodes were characterized by reversible oede
273 imited to azathioprine and prednisone, acute rejection episodes were common, and it was difficult to
278 ent survivals, reason for graft failure, and rejection episodes were evaluated in 221 intestinal reci
282 rast, the 74 mild and 88 indeterminate acute rejection episodes were not associated with unfavorable
285 rrelated well with HA titers and importantly rejection episodes were preempted by a rising relative m
291 red off steroids were treated for subsequent rejection episodes, which were all steroid sensitive, an
292 nts experiencing a first biopsy-proven acute rejection episode while receiving CsA-ME were randomized
293 he lowest MR2* levels were observed in acute rejection episodes with vascular injury i.e. IIA and C4d
295 significantly reduced risk of experiencing a rejection episode within 2 years after surgery compared
296 highly predictive of clinically significant rejection episodes within 1 year of orthotopic heart tra
297 ad multiple biopsy proven or severe clinical rejection episodes within the first 21 days and only one
298 %, or 25.7% incidence of biopsy-proven acute rejection episodes within the first 6 months posttranspl
300 eripheral blood leukocyte genes that trigger rejection episodes would be evident late after ITx durin
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。